Compare AbCellera Biologics Inc (ABCL) vs American Tower Corp (AMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs American Tower Corp — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while American Tower Corp trades at $166.06 (market cap $76.99B). The key difference: American Tower Corp is far larger — about 32.8× AbCellera Biologics Inc's market cap, and American Tower Corp pays a 4.22% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AMT | |
|---|---|---|
Market Cap | $2.35B | $76.99B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $232.35 |
52-Week Low | $2.78 | $162.11 |
Enterprise Value | $1.99B | $120.51B |
Dividend Yield | — | 4.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AMT trades at $165.25, down 0.47% on the day, with a bearish technical signal from moving averages and oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Strong profitability is evident with a net margin of 26.81% and ROE of 82.19%, though valuation ratios like P/E of 26.15 and P/B of 21.44 appear elevated. Recent news highlights steady revenue growth and sustainability initiatives.
The outlook remains positive with a consensus price target of $217, implying significant upside, supported by 38 buy ratings and no sell recommendations. Risks include high debt levels and competitive pressures from satellite technology. The stock offers a solid dividend yield, with the next payment scheduled for July 13, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →
